Evidence map›Paper›PMID 35536017›Full record

SynthesisHuman vaccines & immunotherapeutics2022

Vaccine uptake and barriers to vaccination among at-risk adult populations in the US.

Irina Kolobova, Mawuli Kwame Nyaku, Anna Karakusevic, Daisy Bridge, Iain Fotheringham, Megan O'Brien

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Causes and consequences of undervaccination in adults.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Irina KolobovaCenter for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.
Mawuli Kwame NyakuCenter for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.
Anna KarakusevicAdelphi Values PROVE, Cheshire, UK.
Daisy BridgeAdelphi Values PROVE, Cheshire, UK.
Iain FotheringhamAdelphi Values PROVE, Cheshire, UK.
Megan O'BrienCenter for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.
Adelphi Group (United Kingdom) · GBMerck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To reduce morbidity and mortality associated with vaccine-preventable diseases (VPD), it is imperative that vaccination programs are implemented and prioritized throughout all stages of life across all populations. This study aimed to determine vaccine uptake and barriers to vaccination against VPDs among at-risk adult populations in the United States. We conducted a systematic literature review for articles published between January 2010 and June 2020 and identified 153 publications. The review identified 17 at-risk populations. Vaccine uptake was suboptimal among many populations, with factors including age, gender, and disease severity, associated with uptake. This review identified several barriers that impact vaccine uptake among at-risk populations, with concerns over safety, vaccine costs, lack of insurance, and lack of provider recommendation commonly reported across populations. Embracing a national life-course immunization framework that integrates developing policies, guidelines, and education would be a step to addressing these barriers.

Indexed as

Vaccine-Preventable DiseasesVaccinesAdultHumansImmunization ProgramsRisk FactorsUnited StatesVaccinationVaccinesat-risk populationbarrierslife-course immunizationpopulation healthpublic healthVaccine-preventable diseasesvaccine uptake rate

Identifiers

PMID35536017
PMCPMC9248946
OpenAlexW4280591647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.